Marc Lehman
12.7K posts
Marc Lehman
@markflowchatter
Instividual Trader/Investor https://t.co/6XxJw5gfQN ** INFORMATIONAL PURPOSES ONLY *DO NOT TRADE OFF ANY OF MY INFORMATION**

on $TNGX - LEERINK breaking in very positive on TNGX. "We are doubling our price target to new street high $55 after speaking with management". We just spoke to management and are now more positive on the anticipated data release in pancreatic ductal adenocarcinoma (PDAC) for the combination of vopimetostat plus daraxonrasib, expected this year. The company's enthusiasm appears to have led to the decision to not initiate a pivotal study evaluating vopimetostat (vopi) monotherapy in 2L PDAC, instead focusing on the 1L PDAC opportunity in combination with RAS(ON) inhibitors. Synergistic effects suggest unprecedented activity in PDAC, with ORRs >mid-50s% in 2L PDAC or >40% in 2L+.


Desk comments , Told SCOTUS legal developments affecting $LSTR $CHRW $RXO - positive read through to $KNX $WERN








